荣昌生物制药（烟台）股份有限公司 第二届监事会第十次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 荣昌生物制药（烟台）股份有限公司（以下简称"公司"）第二届监事会第 十次会议，于 2024 年 4 月 26 日在公司会议室以现场方式召开，会议已于 2024 年 4 月 12 日以通讯方式发出会议通知。会议应出席监事 3 名，实际出席监事 3 名，会议由任广科先生主持，会议的召集、召开、表决程序符合《中华人民共和 国公司法》和《荣昌生物制药（烟台）股份有限公司章程》（以下简称"《公司 章程》"）的相关规定，所作决议合法有效。经与会监事表决，会议形成如下决 议： 二、监事会会议审议情况 1、审议通过《关于公司<2024 年第一季度报告>的议案》 监事会认为：公司《2024 年第一季度报告》的编制及审议程序均符合法律、 法规、规范性文件和《公司章程》的要求，格式和内容符合上海证券交易所的各 项规定，报告内容真实、准确、完整地反映了公司本报告期经营管理和财务状况， 不存在任何虚假记载、误导性陈述 ...

荣昌生物制药（烟台）股份有限公司 关于部分募投项目结项并将节余募集资金永久补充 流动资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：688331 证券简称：荣昌生物 公告编号：2024-027 港股代码：09995 港股简称：榮昌生物 荣昌生物制药（烟台）股份有限公司（以下简称"公司"或"荣昌生物"） 于 2024 年 4 月 26 日召开第二届董事会第十三次会议、第二届监事会第十次会议， 审议通过了《关于部分募投项目结项并将节余募集资金永久补充流动资金的议 案》，同意公司将"生物新药产业化项目"结项并将节余募集资金用于永久补充 公司流动资金。保荐机构华泰联合证券有限责任公司（以下简称"华泰联合证券" 或"保荐机构"）对本事项出具了明确同意的核查意见。现就相关情况公告如下： 一、募集资金的基本情况 经中国证券监督管理委员会《关于同意荣昌生物制药（烟台）股份有限公司 首次公开发行股票注册的批复》（证监许可[2022]62 号）核准，公司于 2022 年 3 月 31 日首次公开发行普通股（A 股）5,442 ...

Financial Performance - The company's operating revenue for Q1 2024 was RMB 330,434,802.62, representing a year-on-year increase of 96.41%[4] - The net profit attributable to shareholders was a loss of RMB 348,921,696.49, with a net profit excluding non-recurring items also showing a loss of RMB 345,576,207.04[4] - Total operating revenue for Q1 2024 reached RMB 330,434,802.62, a significant increase from RMB 168,238,991.99 in Q1 2023, representing a growth of 96.5%[18] - The net profit for Q1 2024 was a loss of RMB 348,921,696.49, compared to a loss of RMB 323,774,631.80 in Q1 2023, showing a decline of 7.8%[19] - Total comprehensive loss for Q1 2024 was RMB -372,204,285.59, compared to RMB -326,630,103.58 in Q1 2023, reflecting an increase in losses of 13.9%[19] Cash Flow and Liquidity - The net cash flow from operating activities was negative at RMB 426,289,929.83[4] - Cash flow from operating activities in Q1 2024 was negative at RMB -426,289,929.83, compared to RMB -349,845,397.38 in Q1 2023, indicating a worsening cash flow situation[21] - Cash and cash equivalents at the end of Q1 2024 stood at RMB 619,732,575.42, down from RMB 1,086,332,437.19 at the end of Q1 2023, a decrease of 42.9%[21] - The company reported cash and cash equivalents of CNY 622.79 million, down from CNY 743.39 million[16] - The company received cash inflows from operating activities totaling RMB 289,128,725.27 in Q1 2024, compared to RMB 224,413,979.30 in Q1 2023, an increase of 28.8%[21] - Investment activities resulted in a net cash outflow of RMB -81,362,490.71 in Q1 2024, compared to RMB -584,089,411.54 in Q1 2023, indicating an improvement in investment cash flow[21] Assets and Liabilities - Total assets at the end of the reporting period were RMB 5,478,656,892.82, a decrease of 0.90% from the end of the previous year[5] - As of March 31, 2024, total assets amounted to approximately CNY 5.48 billion, a decrease from CNY 5.53 billion as of December 31, 2023[16] - Current assets totaled CNY 2.20 billion, slightly down from CNY 2.23 billion in the previous period[16] - Total liabilities increased to CNY 2.40 billion from CNY 2.09 billion, indicating a rise in financial obligations[17] - The company's equity attributable to shareholders decreased to CNY 3.08 billion from CNY 3.44 billion[17] Shareholder Information - The total number of common shareholders at the end of the reporting period was 5,422[9] - The number of A-share shareholders totaled 5,397, while H-share shareholders numbered 25, totaling 5,422 shareholders[12] - The company has engaged in securities lending, with 1,425,000 shares lent out, representing 0.26% of total shares[13] Research and Development - R&D investment totaled RMB 331,178,800.01, which accounted for 100.23% of operating revenue, a decrease of 48.20 percentage points compared to the previous year[5][8] - Research and development expenses rose to RMB 331,178,800.01 in Q1 2024, compared to RMB 249,722,218.25 in Q1 2023, reflecting a growth of 32.5%[18] Inventory and Receivables - Inventory levels rose to CNY 751.47 million, compared to CNY 741.56 million previously[16] - Accounts receivable stood at CNY 296.38 million, showing a slight decrease from CNY 297.68 million[16] - The company has a short-term loan of CNY 574.00 million, significantly higher than CNY 284.28 million reported earlier[17]

核查意见 华泰联合证券有限责任公司 关于荣昌生物制药（烟台）股份有限公司部分募投项目结项 并将节余募集资金永久补充流动资金的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合证券"或"保荐机构"） 作为荣昌生物制药（烟台）股份有限公司（以下简称"荣昌生物"或"公司"） 首次公开发行 A 股股票并在科创板上市的保荐机构，根据《证券发行上市保荐 业务管理办法》《科创板上市公司持续监管办法（试行）》《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求（2022 年修订）》《上海证券交 易所科创板股票上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作（2023 年 12 月修订）》等法律法规的规定，对荣昌生物部分募 集资金投资项目结项并将节余募集资金永久补充流动资金事项进行核查，核查情 况如下： 一、募集资金的基本情况 经中国证券监督管理委员会《关于同意荣昌生物制药（烟台）股份有限公司 首次公开发行股票注册的批复》（证监许可[2022]62 号）核准，公司于 2022 年 3 月 31 日首次公开发行普通股（A 股）5,442.6301 万股，每股面值 1 元，每股发 行价 ...

核查意见 华泰联合证券有限责任公司 关于荣昌生物制药（烟台）股份有限公司 调整 2024-2025 年度日常关联交易预计的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合证券"或"保荐机构"） 作为荣昌生物制药（烟台）股份有限公司（以下简称"荣昌生物"或"公司"） 首次公开发行A股股票并在科创板上市持续督导阶段的保荐机构，根据《证券发行 上市保荐业务管理办法》《上海证券交易所科创板股票上市规则》等有关规定， 对荣昌生物本次调整2024-2025年度日常关联交易预计的事项进行了审慎核査，具 体核查情况如下： 一、保荐机构进行的核查工作 华泰联合证券保荐代表人通过与荣昌生物董事、监事、高级管理人员、内部 审计、注册会计师等人员交谈，查阅了本次调整2024-2025年度日常关联交易预计 的信息披露文件、相关董事会决议、独立董事意见，以及各项业务和管理规章制 度，对关联交易的合理性、必要性、有效性进行了核查。 二、关联交易事项 （一）关联方基本情况 1、烟台迈百瑞国际生物医药股份有限公司（以下简称"迈百瑞"） 公司类型：股份有限公司（外商投资、未上市） 法定代表人：房健民 注册资本：40,440.7116万人民 ...

Sales Performance - The sales of Taitasip for the treatment of systemic lupus erythematosus (SLE) saw significant growth in 2023, attributed to its inclusion in the national medical insurance drug list and a commercial team of over 700 professionals covering more than 2,300 hospitals in China[5]. - The sales of Vidiqi monoclonal antibody for the treatment of locally advanced or metastatic gastric cancer (including gastroesophageal junction adenocarcinoma) also experienced notable growth, supported by its inclusion in the national medical insurance drug list and a commercial team of over 600 professionals covering more than 2,000 hospitals in China[5]. - The company reported a significant increase in sales volume for both of its marketed products in 2023, reflecting strong market demand[5]. - The company's revenue increased from RMB 767.8 million in 2022 to RMB 1,076.1 million in 2023, driven by strong sales of its autoimmune product TaiTasi and oncology product VidiCim[30]. Clinical Development - The company initiated three Phase III clinical studies in 2023 for Taitasip, targeting IgA nephropathy, Sjögren's syndrome, and myasthenia gravis, with significant progress reported[5]. - The Phase III clinical trial for systemic lupus erythematosus (SLE) in China was completed in Q3 2022 with positive results, leading to NMPA approval in November 2023[11]. - The Phase III clinical trial for IgA nephropathy has been initiated in China in H1 2023, following positive results from a Phase II trial[13]. - The FDA approved the global Phase III IND for the treatment of adult primary Sjögren's syndrome (pSS) in December 2023[14]. - The company is currently conducting a Phase III clinical trial for HER2-expressing urothelial carcinoma patients and a Phase II trial for HER2-expressing invasive bladder cancer patients in China[6]. Research and Development - The company has established a comprehensive end-to-end drug development capability since its founding in 2008, focusing on unmet medical needs in China and globally[5]. - The company is focused on expanding its market presence both domestically and internationally, maintaining strong momentum in 2024[6]. - The company is developing multiple candidates, including RC88 (Mesothelin ADC), which has the potential to be the next first-in-class product[6]. - The company has a robust pipeline with over ten candidate drugs in various stages of clinical development targeting a wide range of indications[7]. - The company aims to develop more first-in-class and best-in-class products to meet unmet medical needs and provide substantial returns to shareholders[6]. Financial Performance - The company reported a net loss of RMB 1,511,229,000 for the year 2023, compared to a loss of RMB 998,830,000 in 2022[191]. - The net loss for the year was RMB 1,511,229 thousand, an increase from RMB 998,830 thousand in the previous year, indicating a worsening financial position[186]. - Basic loss per share for the year was RMB 2.80, compared to RMB 1.88 in 2022, showing a decline in shareholder value[186]. - Total revenue for 2023 reached RMB 1,076,130 thousand, a 40.1% increase from RMB 767,775 thousand in 2022[186]. - The company’s cash and cash equivalents decreased to RMB 726,552,000 in 2023 from RMB 2,069,180,000 in 2022, a decline of 64.9%[188]. Corporate Governance - The board consists of four executive directors, two non-executive directors, and three independent non-executive directors, ensuring compliance with listing rules regarding independence[59]. - The company has maintained compliance with corporate governance codes throughout the fiscal year ending December 31, 2023[58]. - The board is committed to high standards of corporate governance to protect shareholder interests[58]. - The company has implemented a robust internal control and risk management system, overseen by the board of directors[61]. - The company has purchased liability insurance for directors and senior management to cover potential legal responsibilities[61]. Risk Management - The company faces risks related to delays in clinical development and regulatory approvals, which could severely impact its business[102]. - The company has implemented a risk management framework to identify, assess, and monitor key risks related to its strategic objectives[87]. - The audit committee has conducted an annual review and is confident in the implementation and effectiveness of the group's risk management and internal control procedures[88]. - The company has established a mechanism for the board to obtain independent opinions and advice, ensuring effective governance practices[72]. - The company warns that it cannot ensure the successful development and commercialization of its drug candidates, urging shareholders and potential investors to act cautiously[20][24][27]. Shareholder Engagement - The company emphasizes the importance of maintaining effective communication with investors to enhance transparency and mutual understanding[96]. - The company encourages shareholder participation in meetings to express concerns and provide feedback to the board[95]. - The company has made amendments to its articles of association to improve governance in accordance with regulatory requirements[97]. - The company has not disclosed any significant interests held by the controlling shareholder in contracts important to the group's business during the reporting period[115]. - The company has established employee incentive platforms holding a total of 102,381,891 A-shares as of December 31, 2023[145]. Future Outlook - The company aims to commercialize TaiTasi and VidiCim in China and expand their market presence in 2024[30]. - The company plans to enhance market penetration for Vidiqi monoclonal antibody in 2024 through continued efforts in the oncology sector[5]. - The company plans to utilize all remaining unutilized A-share issuance funds by December 31, 2024, based on current market conditions[44]. - The company aims to enhance its long-term incentive mechanism to attract and retain talent, aligning the interests of shareholders, the company, and core team members[136]. - The company plans to expand its market presence with new product launches and technology developments in the upcoming quarters[124].

华泰联合证券有限责任公司 关于荣昌生物制药（烟台）股份有限公司 2023 年度持续督导跟踪报告 2023年，公司实现营业收入108,295.34万元，较上年同比增长40.26%；但亏 损金额有所增大，公司归属于上市公司股东的净利润-151,122.92万元、归属于上 市公司股东的扣除非经常性损益的净利润-154,334.56万元，均较上年同比减少， 主要系本年各研发管线持续推进，研发费用大幅度增加，另商业化销售投入团队 建设费用和学术推广活动开支等增加。 2023年，公司销售费用为77,518.60万元，较上年同比增长75.90%，主要系公 司为拓展市场，投入了较多的销售团队建设费用和学术推广活动开支；2023年， 公司研发费用130,630.68万元，较上年同比增长33.01%，主要系本年度新药研发 1 管线增加、多个创新药物处于中后期试验研究阶段导致临床试验费、测试费等费 用增加，研发人员增加且员工工资水平上涨；2023年，公司管理费用30,422.68 万元，较上年同比增长14.24%，主要系本年度新建厂房转固后折旧增加。 | 保荐机构名称：华泰联合证券有限责任公司 | 被保荐公司简称：荣昌生物 | | ...

证券代码：688331 证券简称：荣昌生物 荣昌生物制药（烟台）股份有限公司 投资者关系活动记录表 □特定对象调研 □分析师会议 投资者关系活动 □媒体采访 业绩说明会 类别 □新闻发布会 □路演活动 □现场参观 □其他 参与单位名称 2023年度科创板生物制品专场（一）集体业绩说明会 时间 2024年4月15日下午15:00-17:00 上海证券交易所上证路演中心 地点 （网址：http://roadshow.sseinfo.com/） 王威东–董事长 房健民–总经理 公司接待人员 温庆凯–董事会秘书 童少靖–首席财务官兼联席公司秘书 陈云金–独立董事 ...

持续督导现场检查报告 华泰联合证券有限责任公司 关于荣昌生物制药（烟台）股份有限公司 2023年度持续督导现场检查报告 上海证券交易所： 经中国证券监督管理委员会《关于同意荣昌生物制药（烟台）股份有限公司 首次公开发行股票注册的批复》（证监许可〔2022〕62 号）批复，荣昌生物制药 （烟台）股份有限公司（以下简称"荣昌生物"、"上市公司"、"公司"）首次公 开发行人民币普通股（A 股）股票 54,426,301 股，每股面值人民币 1 元，每股发 行价格人民币 48.00 元，募集资金总额为人民币 2,612,462,448.00 元，扣除发行 费用后，实际募集资金净额为人民币 2,505,945,496.76 元。本次发行证券已于 2022 年 3 月 31 日在上海证券交易所上市。华泰联合证券有限责任公司（以下简称"华 泰联合"、"保荐机构"）担任其持续督导保荐机构，持续督导期间为 2022 年 3 月 31 日至 2025 年 12 月 31 日。 根据中国证监会《证券发行上市保荐业务管理办法》和《上海证券交易所科 创板上市公司自律监管指引第 1 号——规范运作》《上海证券交易所上市公司自 律监管指引 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 证券代码：688331 | 证券简称：荣昌生物 | 公告编号：2024-023 | | --- | --- | --- | | 港股代码：09995 | 港股简称：榮昌生物 | | 荣昌生物制药（烟台）股份有限公司 关于参加 2023 年度生物制品专场 集体业绩说明会的公告 荣昌生物制药（烟台）股份有限公司（以下简称"公司"）已于 2024 年 3 月 28 日发布公司 2023 年年度报告，为便于广大投资者更全面深入地了解公司 2023 年度经营成果、财务状况，公司参与了由上海证券交易所主办的 2023 年度生物 制品专场集体业绩说明会，此次活动将采用网络文字互动的方式举行，投资者可 登录上海证券交易所上证路演中心（http://roadshow.sseinfo.com/）参与线上互动 交流。 一、 说明会类型 本次投资者说明会以网络文字互动形式召开，公司将针对 2023 年度的经营 成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的 会议 ...